What is the recommended management for immune thrombocytopenia (ITP)?

Management of Immune Thrombocytopenia (ITP)

For newly diagnosed adult ITP requiring treatment (platelet count <30 × 10⁹/L), initiate corticosteroids as first-line therapy, with the most recent 2026 ASH guidelines now conditionally recommending combination therapy with either rituximab plus corticosteroids or a thrombopoietin receptor agonist (TPO-RA) plus corticosteroids over corticosteroids alone for improved long-term outcomes. 1

Initial Diagnostic Approach

Before initiating treatment, confirm the diagnosis by:

• Testing for HCV and HIV (grade 1B) 2, 3
• Screening for H. pylori and treating if positive (grade 1B for eradication therapy) 2, 3
• Evaluating blood count and smear for abnormalities beyond isolated thrombocytopenia
• Bone marrow examination is NOT necessary in patients with typical ITP presentation, regardless of age (grade 2C) 2, 3

This diagnostic framework is critical because secondary causes (HIV, HCV, H. pylori) require different management strategies and treating the underlying condition may resolve the thrombocytopenia.

When to Treat

Initiate treatment for newly diagnosed patients with platelet count <30 × 10⁹/L (grade 2C) 2

Treatment is NOT required for:

• Asymptomatic patients with platelet counts >30 × 10⁹/L
• Post-splenectomy patients with platelets >30 × 10⁹/L (grade 1C) 2

The goal is maintaining a safe platelet count to prevent bleeding, not normalizing platelet levels, while minimizing treatment toxicity.

First-Line Treatment Options

Standard Approach (2011-2019 Guidelines)

Longer courses of corticosteroids are preferred over shorter courses or IVIg as first-line treatment (grade 2B) 2

However, the 2014 Belgian recommendations and recent evidence emphasize that short courses of corticosteroids should be preferred over prolonged treatment to minimize toxicity 4.

Enhanced First-Line Therapy (2026 Update)

The most recent 2026 ASH guidelines represent a significant shift:

Conditional recommendation for combination therapy:

• Rituximab plus corticosteroids, OR
• TPO-RA plus corticosteroids

Rather than corticosteroids alone 1

This reflects emerging evidence that combination therapy may improve long-term response rates and reduce the need for subsequent interventions.

Adjunctive Therapy for Rapid Response

Add IVIg (1 g/kg as single dose) with corticosteroids when rapid platelet increase is required (grade 2B) 2

Use IVIg or anti-D as first-line if corticosteroids are contraindicated (grade 2C) 2

Second-Line Treatment After Corticosteroid Failure

Strongest Recommendations (2026 Guidelines)

For patients who fail first-line corticosteroids:

1. Thrombopoietin receptor agonists (TPO-RAs) - STRONG recommendation 1

   • Eltrombopag, romiplostim, avatrombopag
   • Highly effective with robust evidence base
   • Well-tolerated for long-term use

2. Rituximab - Conditional recommendation 1

   • May be considered for patients at bleeding risk who failed one line of therapy (grade 2C) 2
   • Offers alternative to splenectomy

3. Splenectomy - For patients who have failed corticosteroid therapy (grade 1B) 2

   • Both laparoscopic and open approaches offer similar efficacy (grade 1C) 2
   • Should be delayed at least 12 months unless severe bleeding or quality of life concerns

Refractory Disease Management

For patients at bleeding risk who relapse after splenectomy or have contraindications:

• TPO-RAs are recommended (grade 1B) 2
• Fostamatinib (Syk inhibitor) is an approved option for refractory patients 5
• Rituximab may be considered (grade 2C) 2

TPO-RAs may be considered even before splenectomy in patients at bleeding risk who failed one line of therapy (grade 2C) 2

Special Populations

Pregnancy

Pregnant patients requiring treatment should receive either corticosteroids or IVIg (grade 1C) 2, 3

Mode of delivery should be based on obstetric indications, not maternal platelet count (grade 2C) 2, 3

Secondary ITP

HIV-associated ITP:

• Treat HIV infection with antiretroviral therapy FIRST unless clinically significant bleeding (grade 1A) 2, 3
• If ITP treatment needed: corticosteroids, IVIg, or anti-D
• Splenectomy preferred over other agents if medical therapy fails (grade 2C)

HCV-associated ITP:

• Consider antiviral therapy in absence of contraindications (grade 2C)
• Monitor platelets closely as interferon may worsen thrombocytopenia
• If ITP treatment needed: IVIg is preferred (grade 2C) 2, 3

H. pylori-associated ITP:

• Administer eradication therapy if H. pylori detected (grade 1B) 2, 3
• Screen all ITP patients for H. pylori (grade 2C)

Critical Pitfalls to Avoid

1. Do not normalize platelet counts - Target safe levels (typically >30 × 10⁹/L) to minimize treatment toxicity
2. Avoid prolonged corticosteroid courses - Use shortest effective duration to reduce adverse effects
3. Do not perform routine bone marrow examination - Only if atypical features present
4. Do not delay TPO-RAs until after splenectomy - Can be used earlier in appropriate patients at bleeding risk
5. Do not use anti-D in patients with hemolysis or anemia from bleeding (grade 1C) 2
6. Screen for secondary causes before labeling as primary ITP - HIV, HCV, H. pylori testing is essential

Treatment Algorithm Summary

Initial presentation → Confirm diagnosis (exclude secondary causes) → Platelet count <30 × 10⁹/L or bleeding:

1. First-line: Corticosteroids (short course preferred), consider adding rituximab or TPO-RA based on 2026 guidelines 1
2. If rapid response needed: Add IVIg
3. Corticosteroid failure: TPO-RA (strong) or rituximab (conditional) 1
4. Persistent disease: Consider splenectomy after 12 months or TPO-RA/fostamatinib if splenectomy contraindicated
5. Post-splenectomy relapse: TPO-RA or fostamatinib

The 2026 ASH guidelines represent the most current evidence-based approach, emphasizing earlier use of combination therapy and TPO-RAs to improve long-term outcomes while minimizing corticosteroid exposure and potentially avoiding splenectomy in many patients.